Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of Two Proellex Formulations in Healthy Volunteers
NCT02141061Phase 1Completed
- Sponsor
- Repros Therapeutics Inc.
- Start
- May 2014
- Primary completion
- Jun 2014
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of telapristone in Uterine Fibroids (UF) and endometriosis (2 arms), sponsored by Repros Therapeutics Inc. Primary endpoints: Pharmacokinetic Comparison at 72 hours and Dose formulation safety up to 2 weeks. Started May 2014; status: completed.
02
Drugs
telapristone
03
Conditions
Uterine Fibroids (UF)endometriosis
Beyond the preview
Go deeper on NCT02141061.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02141061.